Fri, August 10, 2012
Thu, August 9, 2012
Wed, August 8, 2012
Tue, August 7, 2012
Mon, August 6, 2012
Fri, August 3, 2012
Thu, August 2, 2012
[ Thu, Aug 02nd 2012 ] - Market Wire
00 p.m. EDT
Wed, August 1, 2012
[ Wed, Aug 01st 2012 ] - Market Wire
Head of European Operations
Tue, July 31, 2012
Mon, July 30, 2012
Sun, July 29, 2012
Fri, July 27, 2012
Thu, July 26, 2012
Wed, July 25, 2012
Tue, July 24, 2012
[ Tue, Jul 24th 2012 ] - Market Wire
Neogen reports year end results
Mon, July 23, 2012
Sun, July 22, 2012
Sat, July 21, 2012
Fri, July 20, 2012
Thu, July 19, 2012
Wed, July 18, 2012
Tue, July 17, 2012

Sarepta Therapeutics Announces Second Quarter 2012 Financial Results and Corporate Update Conference Call


//health-fitness.news-articles.net/content/2012/ .. esults-and-corporate-update-conference-call.html
Published in Health and Fitness on Tuesday, July 31st 2012 at 5:47 GMT by Market Wire   Print publication without navigation


July 31, 2012 08:30 ET

Sarepta Therapeutics Announces Second Quarter 2012 Financial Results and Corporate Update Conference Call

CAMBRIDGE, MA--(Marketwire - Jul 31, 2012) - Sarepta Therapeutics, Inc. (NASDAQ: [ SRPT ]), a developer of innovative RNA-based therapeutics, will report second quarter 2012 financial results after the NASDAQ Global Market closes on Tuesday, August 7, 2012. Subsequently, at 5:00 p.m., Eastern Time (2:00 p.m., Pacific time), Chris Garabedian, Sarepta's President and CEO, will host a conference call to discuss second quarter financial results and to provide a corporate update.

The conference call may be accessed by dialing 800.446.2782 for domestic and international callers. The passcode for the call is 33002736. Please specify to the operator that you would like to join the "Sarepta second quarter 2012 earnings call." The conference call will be webcast live under the events section of Sarepta's website at [ www.sareptatherapeutics.com ] and will be archived there following the call for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Sarepta Therapeutics

Sarepta Therapeutics -- formerly AVI BioPharma -- is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at [ www.sareptatherapeutics.com ].



Publication Contributing Sources